Search Result

Results for "

glucose tolerance

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SGLT (2) Adrenergic Receptor (1) Aldehyde Dehydrogenase (ALDH) (1) AMPK (3) Apelin Receptor (APJ) (1) Apoptosis (6) Arrestin (1) Bacterial (1) Cannabinoid Receptor (2) Casein Kinase (1) Dipeptidyl Peptidase (3) Drug Intermediate (1) Endogenous Metabolite (8) FABP (1) Fatty Acid Synthase (FASN) (2) FBPase (1) Free Fatty Acid Receptor (3) G protein-coupled Bile Acid Receptor 1 (2) GLP Receptor (3) Glucokinase (2) Glutathione Peroxidase (1) Glycosidase (4) GPR119 (3) HIF/HIF Prolyl-Hydroxylase (1) Insulin Receptor (2) Interleukin Related (2) Isotope-Labeled Compounds (2) MHC (2) NF-κB (3) NO Synthase (1) Orphan GPCR (1) p38 MAPK (2) PDHK (2) PGC-1α (1) Phosphatase (1) Phospholipase (2) PPAR (4) Ras (3) Reference Standards (1) SOD (1) TNF Receptor (2) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (3) Endocrinology (5) Infection (2) Inflammation/Immunology (11) Metabolic Disease (55) Neurological Disease (2)

By Targets:

SGLT (2)

Adrenergic Receptor (1)

Aldehyde Dehydrogenase (ALDH) (1)

AMPK (3)

Apelin Receptor (APJ) (1)

Apoptosis (6)

Arrestin (1)

Bacterial (1)

Cannabinoid Receptor (2)

Casein Kinase (1)

Dipeptidyl Peptidase (3)

Drug Intermediate (1)

Endogenous Metabolite (8)

FABP (1)

Fatty Acid Synthase (FASN) (2)

FBPase (1)

Free Fatty Acid Receptor (3)

G protein-coupled Bile Acid Receptor 1 (2)

GLP Receptor (3)

Glucokinase (2)

Glutathione Peroxidase (1)

Glycosidase (4)

GPR119 (3)

HIF/HIF Prolyl-Hydroxylase (1)

Insulin Receptor (2)

Interleukin Related (2)

Isotope-Labeled Compounds (2)

MHC (2)

NF-κB (3)

NO Synthase (1)

Orphan GPCR (1)

p38 MAPK (2)

PDHK (2)

PGC-1α (1)

Phosphatase (1)

Phospholipase (2)

PPAR (4)

Ras (3)

Reference Standards (1)

SOD (1)

TNF Receptor (2)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (7)

Cardiovascular Disease (3)

Endocrinology (5)

Infection (2)

Inflammation/Immunology (11)

Metabolic Disease (55)

Neurological Disease (2)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Glucose-6-Phosphate Isomerase (GPI) GLUT SGLT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N8522

9,10-Dihydroxystearic acid	Others	Metabolic Disease
9,10-Dihydroxystearic acid is an oxidation product of oleic acid. 9,10-Dihydroxystearic acid can improve glucose tolerance and insulin sensitivity in KKAy mice .

HY-123297

TUG-469	Free Fatty Acid Receptor	Metabolic Disease
TUG-469 is a selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC₅₀ value of 19 nM. TUG-469 is >200-fold selective for FFA1 over FFA4. TUG-469 significantly improves glucose tolerance in pre-diabetic mice. TUG-469 can be used for the research of diabetes .

HY-N9410

Lysophosphatidylcholine 18:2 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC; LPC(18:2/0:0); LysoPC(18:2)	Endogenous Metabolite	Metabolic Disease
Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment .

HY-N7515

Pinocembrin chalcone 2',4',6'-Trihydroxychalcone	Bacterial AMPK	Infection Metabolic Disease Inflammation/Immunology
Pinocembrin chalcone (2',4',6'-Trihydroxychalcone) is an antibacterial compound from Helichrysum Trilineatum. Pinocembrin chalcone facilitates AMP-activated protein kinase (AMPK) activation, improves glucose tolerance, increases muscle FAO and reduces fat accumulation in the liver and skeletal muscles in high-fat diet-induced (HFD) diabetic mice. Pinocembrin chalcone is promising for research of gastric ulcers and diabetes .

HY-10287A

Gosogliptin hydrochloride	Dipeptidyl Peptidase	Metabolic Disease
Gosogliptin hydrochloride is the hydrochloride of Gosogliptin (HY-10287). Gosogliptin (PF-00734200) is a potent, orally active, selective, and competitive inhibitor of DPP-IV, the enzyme mainly responsible for the degradation of the incretin peptides GLP-1 and glucose-dependent insulinotropic polypeptide. Gosogliptin demonstrates rapid and reversible inhibition of plasma DPP-4 activity. Gosogliptin stimulates insulin secretion and improves glucose tolerance .

HY-178982

Apelin agonist 2	Apelin Receptor (APJ)	Metabolic Disease
Apelin agonist 2 is an orally effective APLNR agonist. Apelin agonist 2 can significantly inhibit the accumulation of cAMP (EC₅₀ = 10 nM). Apelin agonist 2 exhibits a significant improvement in glucose tolerance. Apelin agonist 2 can be used to study metabolic diseases such as diabetes .

HY-N0936R

Coixol (Standard) 6-Methoxy-2-benzoxazolinone (Standard); 6-MBOA (Standard)	Others	Inflammation/Immunology
Coixol (6-Methoxy-2-benzoxazolinone; 6-MBOA) is a potent and orally active anti-inflammatory agent. Coixol decreases the iNOS protein expression. Coixol inhibits the production of TNF-α, IL-6, and IL-1β. Coixol improves glucose tolerance and plasma insulin. Coixol decreases the blood glucose level .

HY-161281

α-Glucosidase-IN-49	Glycosidase	Metabolic Disease
α-Glucosidase-IN-49 (compound C23) is a potent inhibitor of α-Glucosidase, with IC₅₀ of 0.52 μM. α-Glucosidase-IN-49 has oral bioactivity that can reduce blood glucose and improve glucose tolerance in mice .

HY-17538A

ZLN005 hydrochloride	PGC-1α	Metabolic Disease
ZLN005 (hydrochloride) is a peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1α) activator. ZLN005 (hydrochloride) can stimulate the expression of PGC-1α and downstream genes in skeletal muscle cells, improve glucose utilization and fatty acid oxidation. ZLN005 (hydrochloride) can increase the transcription of PGC-1α and downstream genes in skeletal muscle of diabetic db/db mice, increase fat oxidation and improve glucose tolerance, pyruvate tolerance and insulin sensitivity .

HY-178447

PPARγ agonist 20	PPAR Glutathione Peroxidase SOD TNF Receptor Interleukin Related NF-κB	Infection Metabolic Disease Endocrinology
PPARγ agonist 20 is a potent, orally active PPAR-γ agonist. PPARγ agonist 20 effectively increases antioxidant defenses (SOD, GSH) and reduces lipid peroxidation. PPARγ agonist 20 can upregulate of Pparg, Glut4, and AdipoQ, suppresses of TNF-α, IL-6, and NF-κB p65. PPARγ agonist 20 significantly lowers fasting blood glucose, improving glucose tolerance, and restoring metabolic balance in Streptozotocin (HY-13753)-Nicotinamide (HY-B0150)-induced diabetic rats. PPARγ agonist 20 can be used for the study of type 2 diabetes .

HY-170874

PPARγ modulator-2	PPAR	Metabolic Disease
PPARγ modulator-2 (Compound (R)-2n) is the reversible modulator for PPARγ that inhibits PPARγ ligand-binding domain (LBD) with an IC₅₀ of 41 nM. PPARγ modulator-2 reduces blood glucose, improves the glucose tolerance and insulin tolerance, and exhibits anti-diabetic efficacy in db/db mouse models .

HY-N2486

Desoxyrhaponticin 1 Publications Verification	Fatty Acid Synthase (FASN) Apoptosis	Cancer
Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.

HY-150012

N-Lactoyl-Phenylalanine 4 Publications Verification Lac-Phe	Endogenous Metabolite	Metabolic Disease Endocrinology
N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance .

HY-117830

CX08005	Phosphatase	Endocrinology
CX08005 is a competitive PTP1B inhibitor. CX08005 can directly enhance the action of insulin in vivo and in vitro and improve insulin resistance .

HY-N13082

Deacetylescin Ia	Others	Metabolic Disease
Deacetylescin Ia (compound 12) is a deacetylated compound with anti-hyperglycemic effects that can be extracted from the debittered Aesculus and deacetylated at the C-22 position. Deacetylescin Ia (100 mg/kg) can inhibit blood glucose elevation in mouse glucose tolerance tests .

HY-164781

KOTX1 MBE1	Aldehyde Dehydrogenase (ALDH)	Metabolic Disease
KOTX1 is an orally active and selective ALDH1A3 inhibitor. KOTX1 improves glucose tolerance, insulin secretion and blood sugar levels in diabetic mouse models .

HY-162893

SX29	Glycosidase	Metabolic Disease
SX29 is an orally active non-competitive α-glucosidase inhibitor with an IC₅₀ value of 2.12 μM. SX29 exhibits hypoglycemic activity, and oral administration of SX29 can reduce blood glucose levels and improve glucose tolerance in diabetic mice .

HY-117446

AS-1669058	GPR119	Metabolic Disease
AS-1669058 is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 induces insulin secretion in response to high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 improved glucose tolerance and reduced blood glucose levels in db/db mice .

HY-125025

SMI 6860766	TNF Receptor	Metabolic Disease Inflammation/Immunology
SMI 6860766, a small molecule inhibitor of CD40-TRAF6 interaction, improves glucose tolerance, reduces immune cell accumulation in adipose tissue, and reduces AT inflammation .

HY-117446A

AS-1669058 free base	GPR119	Metabolic Disease
AS-1669058 free base is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 free base induces insulin secretion induced by high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 free base improved glucose tolerance and reduced blood glucose levels in db/db mice.

HY-110197

6bK TFA 1 Publications Verification	Others	Metabolic Disease
6bK TFA is a potent and selective insulin degrading enzyme (IDE) inhibitor with an IC₅₀ value of 50 nM. 6bK TFA increases circulating insulin in high-fat-fed mice. Acute administration of 6bK TFA enhances glucose tolerance to oral glucose, notably to a greater extent in high-fat-fed mice .

HY-N2486R

Desoxyrhaponticin (Standard)	Reference Standards Fatty Acid Synthase (FASN) Apoptosis	Cancer
Desoxyrhaponticin (Standard) is the analytical standard of Desoxyrhaponticin. This product is intended for research and analytical applications. Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects .

HY-144289

BMS-820132	Glucokinase	Metabolic Disease
BMS-820132 is an orally active and partial glucokinase (GK) activator with a AC₅₀ of 29 nM. BMS-820132 decreases the glucose levels in glucose tolerance test (OGTT) model in normal rats, but not Zucker diabetic fatty (ZDF) rats. BMS-820132 exhibits pharmacological toxicity secondary to strong GK activation .

HY-W709961

5-OAHSA 1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
5-OAHSA (1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate) is a endogenous lipid. 5-OAHSA reduces the level of blood glucose, improves the glucose tolerance, and stimulates the the secretion of GLP-1 and insulin. 5-OAHSA exhibits potential in regulating metabolic and inflammatory responses .

HY-169411

α-Glucosidase-IN-77	Glycosidase	Metabolic Disease
α-Glucosidase-IN-77 (Compound H7) is a non-competitive inhibitor for α-glucosidase with an IC₅₀ of 1.25 μM. α-Glucosidase-IN-77 lowers blood glucose levels, improves glucose tolerance, regulates intestinal microbiota, and exhibits hepatoprotective effect in mouse type 2 diabetes model .

HY-14810

Atigliflozin AVE-2268	SGLT	Metabolic Disease
Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC₅₀s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus .

HY-N0936

Coixol 1 Publications Verification 6-Methoxy-2-benzoxazolinone; 6-MBOA	Others	Inflammation/Immunology
Coixol (6-Methoxy-2-benzoxazolinone;6-MBOA) is a polyphenol extracted from coix (Coix lachryma-jobi L.var.ma-yuen Stapf) with antimicrobial and antitumor activities .

HY-129736A

P32/98	Dipeptidyl Peptidase	Metabolic Disease
P32/98 a potent inhibitor of dipeptidyl peptidase IV with a K_i value of 130 nM. P32/98 improves glucose tolerance, insulin sensitivity and β-cell responsiveness in fatty Zucker rat model .

HY-161892

FABP4-IN-4	FABP	Metabolic Disease Inflammation/Immunology
FABP4-IN-4 (Compound 30) is an orally active inhibitor for FABP, with IC₅₀ of 1.18 μM for FABP 1. FABP4-IN-4 improves the glucose tolerance, reduces the level of blood glucose, plasma lipids and hepatic inflammatory factors, attenuates hepatic steatosis, and exhibits anti-inflammatory effects in mouse diet-induced obesity models .

HY-131334

AMPK activator 4	AMPK	Metabolic Disease
AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect .

HY-129736

P32/98 hemifumarate	Dipeptidyl Peptidase	Metabolic Disease
P32/98 hemifumarateis a potent inhibitor of dipeptidyl peptidase IV with a K_i value of 130 nM. P32/98 hemifumarate improves glucose tolerance, insulin sensitivity and β-cell responsiveness in fatty Zucker rat model .

HY-150012R

N-Lactoyl-Phenylalanine (Standard)	Endogenous Metabolite	Metabolic Disease Endocrinology
N-Lactoyl-Phenylalanine (Standard) is the analytical standard of N-Lactoyl-Phenylalanine. This product is intended for research and analytical applications. N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance .

HY-160602

CPL207280	Free Fatty Acid Receptor	Metabolic Disease
CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes .

HY-133180

YW1128	Wnt β-catenin	Metabolic Disease
YW1128 (compound 3a) is a potent Wnt/β-Catenin inhibitor. YW1128 induces the proteasome degradation of β-catenin and subsequent inhibits the Wnt/β-catenin signaling in cells. YW1128 significantly decreases hepatic lipid accumulation. YW1128 improves glucose tolerance of high fat diet-fed mice without noticeable toxicity. YW1128 down regulates the genes involved in the glucose and fatty acid anabolism .

HY-155553

GPR119 agonist 2	GPR119	Metabolic Disease
GPR119 agonist 2 (compound 43) is an orally active GPR119 agonist. GPR119 agonist 2 shows good pharmacokinetic characteristics in rodents and can effectively improve glucose tolerance in mice and rats. GPR119 agonist 2 has the potential to study type 2 diabetes .

HY-117459

E-3030 free acid	PPAR	Metabolic Disease
E-3030 free acid is a potent dual activator of peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma, exhibiting significant antidiabetic and lipid-modulating effects. E-3030 decreases blood glucose, triglyceride, non-esterified fatty acids, and insulin levels, while increasing blood adiponectin levels. E-3030 improves glucose tolerance and shows remarkable triglyceride- and non-high-density lipoprotein cholesterol-lowering effects in animal models.

HY-173130

α-Glucosidase-IN-86	Glycosidase	Metabolic Disease Inflammation/Immunology
α-Glucosidase-IN-86 (Compound A4) is an orally active α-glucosidase inhibitor with an IC₅₀ of 2.72 μM. α-Glucosidase-IN-86 has high safety in mice. α-Glucosidase-IN-86 can reduce fasting blood glucose levels, improve glucose tolerance, regulate blood lipids, and has antioxidant effects in diabetic mice. α-Glucosidase-IN-86 can be used for the research of diabetes .

HY-150012S1

N-Lactoyl-Phenylalanine-13C6 Lac-Phe-¹³C₆	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease Endocrinology
N-Lactoyl-Phenylalanine- ¹³C₆ (Lac-Phe- ¹³C₆) is ¹³C labeled N-Lactoyl-Phenylalanine. N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance .

HY-P1434

[Pro3]-GIP (mouse)	Insulin Receptor	Metabolic Disease
[Pro3]-GIP (mouse) is a GIP receptor antagonist (IC₅₀: 2.6 μM). [Pro3]-GIP (mouse) improves glucose tolerance and insulin sensitivity in ob/ob mice. [Pro3]-GIP (mouse) can be used for research of type 2 diabetes .

HY-175701

CT-996 RO7795081; RG6652	GLP Receptor Arrestin	Metabolic Disease
CT-996 is an orally active GLP-1RA agonist, with an EC₅₀ of 0.49 nM. CT-996 reduces the β-arrestin recruitment and GLP-1R internalization. CT-996 suppresses postprandial blood glucose following a mixed meal tolerance test (MMTT) in mice expressing the human GLP-1 receptor and enhances glucose stimulated insulin secretion (GSIS) during an intravenous glucose challenge in obese monkeys. CT-996 can be used for the study of type 2 diabetes (T2D) and obesity .

HY-177297

LCZ960 NVP-LCZ960	Glucokinase	Metabolic Disease
LCZ960 is an orally active glucokinase (GK) activator. LCZ960 stimulates GK activity in hepatocytes in vitro and stimulates glucose uptake in vivo through hepatic GK activation. LCZ960 lowers blood glucose in mice with diet-induced obesity (DIO). LCZ960 maintains normoglycemia and improves glucose tolerance in DIO mice and rats. LCZ960 stimulates glycogen synthase flux and increases hepatic glycogen turnover in rats. LCZ960 induces increased hepatic glycogen recycling. LCZ960 can be used to study high-fat diet-induced obesity and type 2 diabetes .

HY-146725

FBPase-IN-1	FBPase	Metabolic Disease
FBPase-IN-1 is a potent FBPase (Fructose-1,6-bisphosphatase) inhibitor for Type 2 diabetes (T2D) study with an IC₅₀ of 0.22 μM. FBPase-IN-1 can reduce blood glucose levels and ameliorate glucose tolerance. FBPase-IN-1 modifies the C128 site, regulates the N125-S124-S123 allosteric pathway of FBPase and affects the catalytic activity of FBPase .

HY-133559

VSP-77	PPAR	Metabolic Disease
VSP-77 is an orally active PPARγ agonist. VSP-77 selectively upregulates the expression of insulin sensitivity-related genes (Glut4 and Adiponectin) by inhibiting CDK5-mediated phosphorylation of PPARγ at Ser-273. VSP-77 significantly improves glucose tolerance, reduces fasting blood glucose and insulin levels in high-fat diet (HFD)-induced diabetic mouse models. VSP-77 can be used for the study of diabetes .

HY-125327

YM-543	SGLT	Metabolic Disease
YM-543 is a selective SGLT2 inhibitor that effectively reduces hyperglycemia in type 2 diabetic mice through increased urinary glucose excretion. YM-543 demonstrates potent inhibition of both mouse and human SGLT2 activities at nanomolar concentrations. YM-543, when administered orally, significantly improves glucose tolerance in diabetic models and sustains its effects for over 12 hours. YM-543, in combination with other antidiabetic agents like rosiglitazone or metformin, enhances the therapeutic effects on diabetic symptoms. YM-543 does not affect blood glucose levels in normal mice, indicating its specificity for diabetic conditions.

HY-147678

GPR40 agonist 5	Free Fatty Acid Receptor	Metabolic Disease
GPR40 agonist 5 (compound I-14) is an orally active and potent GPR40 (G protein coupled receptor 40) agonist, with an EC₅₀ of 47 nM. GPR40 agonist 5 decreases the levels of blood glucose and improves the glucose tolerance. GPR40 agonist 5 has sufficient effectiveness for the control of hyperglycemia state in type 2 diabetic mice . GPR40 agonist 5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P0165B

Taspoglutide acetate ITM077 acetate; R1583 acetate; BIM51077 acetate	GLP Receptor	Metabolic Disease
Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an K_i value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC₅₀ = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .

HY-139792

Besigliptin tosylate SHR117887	Endogenous Metabolite	Metabolic Disease
Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .

HY-106863

BRL 35135	Adrenergic Receptor	Metabolic Disease
BRL 35135 is a potent and selective β3-adrenergic receptor agonist. BRL 35135 can dose dependently increase energy expenditure, reduce weight, and only reduce fat without reducing muscle protein. BRL 35135 can significantly improve glucose tolerance and insulin sensitivity. BRL 35135 can be used to study metabolic conditions such as obesity and diabetes .

HY-13991A

(S)-CCG-1423	Ras	Metabolic Disease Cancer
(S)-CCG-1423 is an inhibitor of Rho signaling that blocks the nuclear import of MRTF-A. (S)-CCG-1423 reduces the nuclear accumulation of MRTF-A and improves glucose uptake and tolerance in insulin-resistance mice in vivo. (S)-CCG-1423 exhibits higher inhibition activity than the SR- and the R-isomers of CCG-1423 (HY-13991). (S)-CCG-1423 can be used for the research of cancer and diabetes .

HY-178857

CB1 antagonist 6	Cannabinoid Receptor	Metabolic Disease
CB1 antagonist 6 (Compound 11jE2) is an orally active CB1R antagonist, with an IC₅₀ value of 23 nM. CB1 antagonist 6 significantly reduces food intake and body weight, improves glucose tolerance and insulin resistance, and decreases serum ALT and AST levels in diet-induced obese (DIO) mice, demonstrating hepatoprotective effects. CB1 antagonist 6 can be used for the study of metabolic syndrome (obesity, diabetes) .

Cat. No.	Product Name	Target	Research Area

HY-P1434

[Pro3]-GIP (mouse)	Insulin Receptor	Metabolic Disease
[Pro3]-GIP (mouse) is a GIP receptor antagonist (IC₅₀: 2.6 μM). [Pro3]-GIP (mouse) improves glucose tolerance and insulin sensitivity in ob/ob mice. [Pro3]-GIP (mouse) can be used for research of type 2 diabetes .

HY-W003222

N-tert-Boc-cis-4-fluoro-L-proline	Drug Intermediate	Metabolic Disease
N-tert-Boc-cis-4-fluoro-L-proline (Compound 11) is a drug intermediate for the synthesis of 4-fluoropyrrolidine-2-carbonitrile DPP-4 inhibitor. N-tert-Boc-cis-4-fluoro-L-proline can be used to study type 2 diabetes .

HY-P3247

[D-Ala2]-GIP (human)	Insulin Receptor	Neurological Disease Metabolic Disease
[D-Ala2]-GIP (human) is a GIP receptor agonist (EC₅₀ = 630 pM). [D-Ala2]-GIP (human) improves glucose tolerance. [D-Ala2]-GIP (human) shows neuroprotective activity in MPTP (HY-W114750)-induced Parkinson's disease model. [D-Ala2]-GIP (human) also improves cognitive function and hippocampal synaptic plasticity in obese diabetic rats. [D-Ala2]-GIP (human) can be used for research of type 2 diabetes, Parkinson's disease, etc

HY-P0165B

Taspoglutide acetate ITM077 acetate; R1583 acetate; BIM51077 acetate	GLP Receptor	Metabolic Disease
Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an K_i value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC₅₀ = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N8522

9,10-Dihydroxystearic acid	Classification of Application Fields Ricinus communis L. Ketones, Aldehydes, Acids Source classification Metabolic Disease Euphorbiaceae Plants Disease Research Fields	Others
9,10-Dihydroxystearic acid is an oxidation product of oleic acid. 9,10-Dihydroxystearic acid can improve glucose tolerance and insulin sensitivity in KKAy mice .

HY-N9410

Lysophosphatidylcholine 18:2 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC; LPC(18:2/0:0); LysoPC(18:2)	Infection Natural Products Classification of Application Fields Source classification Disease markers Endocrine diseases Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment .

HY-N7515

Pinocembrin chalcone 2',4',6'-Trihydroxychalcone	Chalcones Flavonoids other families Classification of Application Fields Source classification Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields	Bacterial AMPK
Pinocembrin chalcone (2',4',6'-Trihydroxychalcone) is an antibacterial compound from Helichrysum Trilineatum. Pinocembrin chalcone facilitates AMP-activated protein kinase (AMPK) activation, improves glucose tolerance, increases muscle FAO and reduces fat accumulation in the liver and skeletal muscles in high-fat diet-induced (HFD) diabetic mice. Pinocembrin chalcone is promising for research of gastric ulcers and diabetes .

HY-N2486

Desoxyrhaponticin 1 Publications Verification	Monophenols Stilbenes Classification of Application Fields Polygonaceae Source classification Rheum rhabarbarum Linnaeus Phenols Plants Rheum tanguticum Disease Research Fields Cancer	Fatty Acid Synthase (FASN) Apoptosis
Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.

HY-150012

N-Lactoyl-Phenylalanine 4 Publications Verification Lac-Phe	Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance .

HY-N2486R

Desoxyrhaponticin (Standard)	Monophenols Stilbenes Polygonaceae Source classification Rheum rhabarbarum Linnaeus Phenols Plants Rheum tanguticum	Reference Standards Fatty Acid Synthase (FASN) Apoptosis
Desoxyrhaponticin (Standard) is the analytical standard of Desoxyrhaponticin. This product is intended for research and analytical applications. Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects .

HY-N0936

Coixol 1 Publications Verification 6-Methoxy-2-benzoxazolinone; 6-MBOA	Infection Classification of Application Fields Ketones, Aldehydes, Acids Gramineae Coix lacryma-jobi Linn. Plants Disease Research Fields	Others
Coixol (6-Methoxy-2-benzoxazolinone;6-MBOA) is a polyphenol extracted from coix (Coix lachryma-jobi L.var.ma-yuen Stapf) with antimicrobial and antitumor activities .

HY-N0936R

Coixol (Standard) 6-Methoxy-2-benzoxazolinone (Standard); 6-MBOA (Standard)	Ketones, Aldehydes, Acids Gramineae Marine natural products Source classification Coix lacryma-jobi Linn. Plants	Others
Coixol (6-Methoxy-2-benzoxazolinone; 6-MBOA) is a potent and orally active anti-inflammatory agent. Coixol decreases the iNOS protein expression. Coixol inhibits the production of TNF-α, IL-6, and IL-1β. Coixol improves glucose tolerance and plasma insulin. Coixol decreases the blood glucose level .

HY-N13082

Deacetylescin Ia	Aesculus chinensis Bunge Triterpenes Terpenoids Hippocastanaceae Source classification Plants	Others
Deacetylescin Ia (compound 12) is a deacetylated compound with anti-hyperglycemic effects that can be extracted from the debittered Aesculus and deacetylated at the C-22 position. Deacetylescin Ia (100 mg/kg) can inhibit blood glucose elevation in mouse glucose tolerance tests .

HY-150012R

N-Lactoyl-Phenylalanine (Standard)	Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
N-Lactoyl-Phenylalanine (Standard) is the analytical standard of N-Lactoyl-Phenylalanine. This product is intended for research and analytical applications. N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance .

HY-N15721

Tryptophan-cholic acid Trp-CA	Triterpenes Terpenoids Source classification Endogenous metabolite	Orphan GPCR
Tryptophan-cholic acid (Trp-CA) is a microbial amino-acid-conjugated bile acid, serving as an endogenous ligand and agonist of the orphan G protein-coupled receptor (GPCR) MRGPRE. Tryptophan-cholic acid activates MRGPRE, promoting the secretion of glucagon-like peptide-1 (GLP-1) through the Gs-cAMP and β-arrestin-1-ALDOA signaling pathways, thereby improving glucose tolerance in diabetic mice. Tryptophan-cholic acid is promising for research of type 2 diabetes .

HY-N8518R

Malabaricone C (Standard)	Source classification Phenols Polyphenols Myristicaceae Plants Myristica fragrans Houtt.	Phospholipase p38 MAPK Apoptosis NF-κB
Malabaricone C is an orally active and noncompetitive sphingomyelin synthase (SMS) inhibitor with IC50 values of 3 μM and 1.5 μM for SMS 1 and SMS 2, respectively. Malabaricone C reduces body weight gain, improves glucose tolerance, and decreases lipid accumulation in the liver, showing significant prevention of high fat diet-induced fatty liver in mice. Malabaricone C has anti-inflammatory effects, which is found in the fruits of Myristica cinnamomea King. Malabaricone C is promising for research of obesity and immunological disorders caused due to hyper-activation of T-cells .

HY-N8518

Malabaricone C 3 Publications Verification	Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Myristicaceae Plants Myristica fragrans Houtt. Disease Research Fields	Phospholipase p38 MAPK Apoptosis NF-κB
Malabaricone C is an orally active and noncompetitive sphingomyelin synthase (SMS) inhibitor with IC₅₀ values of 3 μM and 1.5 μM for SMS 1 and SMS 2, respectively. Malabaricone C reduces body weight gain, improves glucose tolerance, and decreases lipid accumulation in the liver, showing significant prevention of high fat diet-induced fatty liver in mice. Malabaricone C has anti-inflammatory effects, which is found in the fruits of Myristica cinnamomea King. Malabaricone C is promising for research of obesity and immunological disorders caused due to hyper-activation of T-cells .

HY-155156

PF-07238025	Cardiovascular Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC₅₀=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-155157

PF-07247685	Cardiovascular Disease Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC₅₀=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .

Cat. No.	Product Name	Chemical Structure

HY-150012S1

N-Lactoyl-Phenylalanine-13C6
N-Lactoyl-Phenylalanine- ¹³C₆ (Lac-Phe- ¹³C₆) is ¹³C labeled N-Lactoyl-Phenylalanine. N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance .

HY-126855S

Cholic acid 7-sulfate-d4

Cholic acid 7-sulfate-d₄ (7-Sulfocholic acid-d₄) is the deuterium labeled Cholic acid 7-sulfate (HY-126855). Cholic acid 7-sulfate is a selective agonist targeting TGR5 (EC₅₀=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks